^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Betalutin (177Lu-satetraxetan-lilotomab)

    i
    Other names: 177Lu-DOTA-tetulomab, 177Lu-DOTA-HH1, Lymrit 37-05, HH1
    Company:
    Nordic Nanovector
    Drug class:
    Ionizing radiation emitter, CD37 inhibitor
    Related drugs:
    4ms
    LYMRIT-37-07: Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL (clinicaltrials.gov)
    P1, N=7, Completed, Nordic Nanovector | Phase classification: P1b --> P1
    Phase classification • Combination therapy
    |
    Rituxan (rituximab) • Betalutin (177Lu-satetraxetan-lilotomab)
    over4years
    The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines (ASH 2019)
    The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin®) is currently being evaluated as monotherapy in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL), as well as in a phase 1b trial in combination with rituximab for patients with relapsed/refractory FL. These findings may be of potential relevance for ongoing clinical trials of 177Lu-lilotomab satetraxetan in relapsed, ASCT-non-eligible DLBCL, and may also be more generally applicable to other 177Lu-based RITs and alternative radionuclide utilizing targeted therapies. Future pre-clinical investigations are required to elucidate the potential application of CDK1/2 and AURKA/B inhibitors as a strategy to revert RIT resistance in TP53 deficient cancers.
    Preclinical
    |
    TP53 (Tumor protein P53) • AURKA (Aurora kinase A) • CDK1 (Cyclin-dependent kinase 1)
    |
    Rituxan (rituximab) • Betalutin (177Lu-satetraxetan-lilotomab)